Lessons in initiating insulin in clinical practice
Abstract Insulin therapy in type 2 diabetes (T2DM) can produce greater improvements in fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) than oral antidiabetic drugs (OADs). There is a growing trend to recommend initiation of insulin in T2DM patients sooner in the course of the disease,...
Gespeichert in:
| Veröffentlicht in: | Diabetes research and clinical practice 2008-09, Vol.81, p.S16-S22 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S22 |
|---|---|
| container_issue | |
| container_start_page | S16 |
| container_title | Diabetes research and clinical practice |
| container_volume | 81 |
| creator | Sharma, Surendra K Yeo, Jing Ping Garber, Alan |
| description | Abstract Insulin therapy in type 2 diabetes (T2DM) can produce greater improvements in fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) than oral antidiabetic drugs (OADs). There is a growing trend to recommend initiation of insulin in T2DM patients sooner in the course of the disease, and good results have been achieved in insulin-naïve patients during randomised, controlled trials, often using aggressive dose titration algorithms. The Physicians’ Routine Evaluation of Safety & Efficacy NovoMix® 30 Therapy (PRESENT) study was a 6-month observational study of the safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) as monotherapy or in combination with OADs in inadequately controlled patients with T2DM. This review article compares results from those patients who entered the study insulin-naïve (either with or without previous OAD treatment), with results from randomised, controlled trials of BIAsp 30 in insulin-naïve T2DM patients. It aims to provide guidance on the initiation of insulin in patients with T2DM, focusing on the efficacy of BIAsp 30 when used for this purpose, and highlighting both the low risk of hypoglycaemia associated with therapy, and the availability of delivery devices that can minimise injection site discomfort and help to overcome psychological insulin resistance. |
| doi_str_mv | 10.1016/j.diabres.2008.06.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69435354</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0168822708002775</els_id><sourcerecordid>69435354</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-f99fbd2f0e0ad5ee9babb87030c1337109a2a21baf55a1377fcc622b9ba4f4893</originalsourceid><addsrcrecordid>eNqFkd9LwzAQgIMobk7_BGVPvrVekrZJXxQZ_oKBD-pzSNOrpHbtTFph_73pNhF8EQJ3hO_uuO8IOacQU6DZVR2XVhcOfcwAZAxZDJAfkCmVgkWSMXFIpoGT23xCTryvASDjSXpMJlRmgnGQU8KW6H3X-rltw7O91b1t30Pqh2b7NTchWqOb-dpp01uDp-So0o3Hs32ckbf7u9fFY7R8fnha3C4jk1DZR1WeV0XJKkDQZYqYF7oopAAOhnIuKOSaaUYLXaWpplyIypiMsSJwSZXInM_I5a7v2nWfA_peraw32DS6xW7wKssTnvI0CWC6A43rvHdYqbWzK-02ioIaZala7WWpUZaCTAVZoe5iP2AoVlj-Vu3tBOBmB2BY88uiU95YbA2W1qHpVdnZf0dc_-nwo_MDN-jrbnBtcKio8kyBehkvNh4MJAATIuXf5COSVQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69435354</pqid></control><display><type>article</type><title>Lessons in initiating insulin in clinical practice</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Sharma, Surendra K ; Yeo, Jing Ping ; Garber, Alan</creator><creatorcontrib>Sharma, Surendra K ; Yeo, Jing Ping ; Garber, Alan</creatorcontrib><description>Abstract Insulin therapy in type 2 diabetes (T2DM) can produce greater improvements in fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) than oral antidiabetic drugs (OADs). There is a growing trend to recommend initiation of insulin in T2DM patients sooner in the course of the disease, and good results have been achieved in insulin-naïve patients during randomised, controlled trials, often using aggressive dose titration algorithms. The Physicians’ Routine Evaluation of Safety & Efficacy NovoMix® 30 Therapy (PRESENT) study was a 6-month observational study of the safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) as monotherapy or in combination with OADs in inadequately controlled patients with T2DM. This review article compares results from those patients who entered the study insulin-naïve (either with or without previous OAD treatment), with results from randomised, controlled trials of BIAsp 30 in insulin-naïve T2DM patients. It aims to provide guidance on the initiation of insulin in patients with T2DM, focusing on the efficacy of BIAsp 30 when used for this purpose, and highlighting both the low risk of hypoglycaemia associated with therapy, and the availability of delivery devices that can minimise injection site discomfort and help to overcome psychological insulin resistance.</description><identifier>ISSN: 0168-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/j.diabres.2008.06.009</identifier><identifier>PMID: 18672308</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>BIAsp 30 ; Blood Glucose - drug effects ; Blood Glucose - metabolism ; Clinical Trials as Topic ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetic Angiopathies - prevention & control ; Endocrinology & Metabolism ; Glycated Hemoglobin A - metabolism ; Humans ; Hyperglycemia - prevention & control ; Hypoglycemic Agents - therapeutic use ; Insulin - therapeutic use ; Insulin analogue ; Insulin initiation ; Multicenter Studies as Topic ; Observational study</subject><ispartof>Diabetes research and clinical practice, 2008-09, Vol.81, p.S16-S22</ispartof><rights>2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-f99fbd2f0e0ad5ee9babb87030c1337109a2a21baf55a1377fcc622b9ba4f4893</citedby><cites>FETCH-LOGICAL-c418t-f99fbd2f0e0ad5ee9babb87030c1337109a2a21baf55a1377fcc622b9ba4f4893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.diabres.2008.06.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18672308$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sharma, Surendra K</creatorcontrib><creatorcontrib>Yeo, Jing Ping</creatorcontrib><creatorcontrib>Garber, Alan</creatorcontrib><title>Lessons in initiating insulin in clinical practice</title><title>Diabetes research and clinical practice</title><addtitle>Diabetes Res Clin Pract</addtitle><description>Abstract Insulin therapy in type 2 diabetes (T2DM) can produce greater improvements in fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) than oral antidiabetic drugs (OADs). There is a growing trend to recommend initiation of insulin in T2DM patients sooner in the course of the disease, and good results have been achieved in insulin-naïve patients during randomised, controlled trials, often using aggressive dose titration algorithms. The Physicians’ Routine Evaluation of Safety & Efficacy NovoMix® 30 Therapy (PRESENT) study was a 6-month observational study of the safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) as monotherapy or in combination with OADs in inadequately controlled patients with T2DM. This review article compares results from those patients who entered the study insulin-naïve (either with or without previous OAD treatment), with results from randomised, controlled trials of BIAsp 30 in insulin-naïve T2DM patients. It aims to provide guidance on the initiation of insulin in patients with T2DM, focusing on the efficacy of BIAsp 30 when used for this purpose, and highlighting both the low risk of hypoglycaemia associated with therapy, and the availability of delivery devices that can minimise injection site discomfort and help to overcome psychological insulin resistance.</description><subject>BIAsp 30</subject><subject>Blood Glucose - drug effects</subject><subject>Blood Glucose - metabolism</subject><subject>Clinical Trials as Topic</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetic Angiopathies - prevention & control</subject><subject>Endocrinology & Metabolism</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Humans</subject><subject>Hyperglycemia - prevention & control</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - therapeutic use</subject><subject>Insulin analogue</subject><subject>Insulin initiation</subject><subject>Multicenter Studies as Topic</subject><subject>Observational study</subject><issn>0168-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkd9LwzAQgIMobk7_BGVPvrVekrZJXxQZ_oKBD-pzSNOrpHbtTFph_73pNhF8EQJ3hO_uuO8IOacQU6DZVR2XVhcOfcwAZAxZDJAfkCmVgkWSMXFIpoGT23xCTryvASDjSXpMJlRmgnGQU8KW6H3X-rltw7O91b1t30Pqh2b7NTchWqOb-dpp01uDp-So0o3Hs32ckbf7u9fFY7R8fnha3C4jk1DZR1WeV0XJKkDQZYqYF7oopAAOhnIuKOSaaUYLXaWpplyIypiMsSJwSZXInM_I5a7v2nWfA_peraw32DS6xW7wKssTnvI0CWC6A43rvHdYqbWzK-02ioIaZala7WWpUZaCTAVZoe5iP2AoVlj-Vu3tBOBmB2BY88uiU95YbA2W1qHpVdnZf0dc_-nwo_MDN-jrbnBtcKio8kyBehkvNh4MJAATIuXf5COSVQ</recordid><startdate>20080901</startdate><enddate>20080901</enddate><creator>Sharma, Surendra K</creator><creator>Yeo, Jing Ping</creator><creator>Garber, Alan</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080901</creationdate><title>Lessons in initiating insulin in clinical practice</title><author>Sharma, Surendra K ; Yeo, Jing Ping ; Garber, Alan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-f99fbd2f0e0ad5ee9babb87030c1337109a2a21baf55a1377fcc622b9ba4f4893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>BIAsp 30</topic><topic>Blood Glucose - drug effects</topic><topic>Blood Glucose - metabolism</topic><topic>Clinical Trials as Topic</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetic Angiopathies - prevention & control</topic><topic>Endocrinology & Metabolism</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Humans</topic><topic>Hyperglycemia - prevention & control</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - therapeutic use</topic><topic>Insulin analogue</topic><topic>Insulin initiation</topic><topic>Multicenter Studies as Topic</topic><topic>Observational study</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sharma, Surendra K</creatorcontrib><creatorcontrib>Yeo, Jing Ping</creatorcontrib><creatorcontrib>Garber, Alan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sharma, Surendra K</au><au>Yeo, Jing Ping</au><au>Garber, Alan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lessons in initiating insulin in clinical practice</atitle><jtitle>Diabetes research and clinical practice</jtitle><addtitle>Diabetes Res Clin Pract</addtitle><date>2008-09-01</date><risdate>2008</risdate><volume>81</volume><spage>S16</spage><epage>S22</epage><pages>S16-S22</pages><issn>0168-8227</issn><eissn>1872-8227</eissn><abstract>Abstract Insulin therapy in type 2 diabetes (T2DM) can produce greater improvements in fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) than oral antidiabetic drugs (OADs). There is a growing trend to recommend initiation of insulin in T2DM patients sooner in the course of the disease, and good results have been achieved in insulin-naïve patients during randomised, controlled trials, often using aggressive dose titration algorithms. The Physicians’ Routine Evaluation of Safety & Efficacy NovoMix® 30 Therapy (PRESENT) study was a 6-month observational study of the safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) as monotherapy or in combination with OADs in inadequately controlled patients with T2DM. This review article compares results from those patients who entered the study insulin-naïve (either with or without previous OAD treatment), with results from randomised, controlled trials of BIAsp 30 in insulin-naïve T2DM patients. It aims to provide guidance on the initiation of insulin in patients with T2DM, focusing on the efficacy of BIAsp 30 when used for this purpose, and highlighting both the low risk of hypoglycaemia associated with therapy, and the availability of delivery devices that can minimise injection site discomfort and help to overcome psychological insulin resistance.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>18672308</pmid><doi>10.1016/j.diabres.2008.06.009</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8227 |
| ispartof | Diabetes research and clinical practice, 2008-09, Vol.81, p.S16-S22 |
| issn | 0168-8227 1872-8227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69435354 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | BIAsp 30 Blood Glucose - drug effects Blood Glucose - metabolism Clinical Trials as Topic Diabetes Mellitus, Type 2 - drug therapy Diabetic Angiopathies - prevention & control Endocrinology & Metabolism Glycated Hemoglobin A - metabolism Humans Hyperglycemia - prevention & control Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Insulin analogue Insulin initiation Multicenter Studies as Topic Observational study |
| title | Lessons in initiating insulin in clinical practice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T14%3A10%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lessons%20in%20initiating%20insulin%20in%20clinical%20practice&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Sharma,%20Surendra%20K&rft.date=2008-09-01&rft.volume=81&rft.spage=S16&rft.epage=S22&rft.pages=S16-S22&rft.issn=0168-8227&rft.eissn=1872-8227&rft_id=info:doi/10.1016/j.diabres.2008.06.009&rft_dat=%3Cproquest_cross%3E69435354%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69435354&rft_id=info:pmid/18672308&rft_els_id=1_s2_0_S0168822708002775&rfr_iscdi=true |